- Home
- RLJ vs CVAC Comparison
RLJ vs CVAC Comparison
Compare RLJ & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLJ
- CVAC
- Stock Information
- Founded
- RLJ 2011
- CVAC 2000
- Country
- RLJ United States
- CVAC Germany
- Employees
- RLJ N/A
- CVAC N/A
- Industry
- RLJ Real Estate Investment Trusts
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- RLJ Real Estate
- CVAC Health Care
- Exchange
- RLJ Nasdaq
- CVAC Nasdaq
- Market Cap
- RLJ 1.1B
- CVAC 1.2B
- IPO Year
- RLJ 2011
- CVAC 2020
- Fundamental
- Price
- RLJ $7.03
- CVAC $5.41
- Analyst Decision
- RLJ Hold
- CVAC Hold
- Analyst Count
- RLJ 6
- CVAC 3
- Target Price
- RLJ $9.21
- CVAC $6.83
- AVG Volume (30 Days)
- RLJ 2.2M
- CVAC 404.4K
- Earning Date
- RLJ 11-05-2025
- CVAC 11-11-2025
- Dividend Yield
- RLJ 8.50%
- CVAC N/A
- EPS Growth
- RLJ N/A
- CVAC N/A
- EPS
- RLJ 0.20
- CVAC 1.01
- Revenue
- RLJ $1,367,020,000.00
- CVAC $599,540,810.00
- Revenue This Year
- RLJ N/A
- CVAC N/A
- Revenue Next Year
- RLJ $2.26
- CVAC $23.83
- P/E Ratio
- RLJ $35.44
- CVAC $5.40
- Revenue Growth
- RLJ 1.40
- CVAC 675.15
- 52 Week Low
- RLJ $6.16
- CVAC $2.37
- 52 Week High
- RLJ $10.84
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- RLJ 33.84
- CVAC 53.41
- Support Level
- RLJ $6.95
- CVAC $5.33
- Resistance Level
- RLJ $7.29
- CVAC $5.45
- Average True Range (ATR)
- RLJ 0.17
- CVAC 0.03
- MACD
- RLJ -0.06
- CVAC 0.01
- Stochastic Oscillator
- RLJ 9.88
- CVAC 66.10
About RLJ RLJ Lodging Trust of Beneficial Interest $0.01 par value
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.